{"id":"placebo-matching-seroquel-xr","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo matching formulations are inactive preparations manufactured to be identical or nearly identical in appearance, taste, and physical properties to the active drug being studied. In this case, it matches Seroquel XR to enable blinded clinical trial designs where neither patients nor researchers know who receives active quetiapine or placebo, ensuring unbiased assessment of drug efficacy and safety.","oneSentence":"This is a placebo formulation designed to match the appearance and characteristics of Seroquel XR (quetiapine extended-release) for use as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:15.584Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control for Seroquel XR studies"}]},"trialDetails":[{"nctId":"NCT00457197","phase":"PHASE4","title":"Quetiapine for Bipolar Disorder and Alcohol Dependence","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-03","conditions":"Bipolar Disorder, Alcohol Dependence","enrollment":90},{"nctId":"NCT01725282","phase":"PHASE2","title":"Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-12-14","conditions":"Major Depressive Disorder","enrollment":172},{"nctId":"NCT01727726","phase":"PHASE3","title":"A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-12","conditions":"Depressive Disorder, Depression, Depressive Disorder, Major","enrollment":2182},{"nctId":"NCT01256177","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-12","conditions":"Bipolar Depression","enrollment":361},{"nctId":"NCT00619892","phase":"PHASE4","title":"A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients","status":"COMPLETED","sponsor":"Indiana University","startDate":"2008-02","conditions":"Panic Disorder","enrollment":26},{"nctId":"NCT00746421","phase":"PHASE4","title":"Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder","status":"TERMINATED","sponsor":"Emory University","startDate":"2010-01","conditions":"Bipolar Disorder, Cognitive Impairment","enrollment":32},{"nctId":"NCT00631748","phase":"NA","title":"Quetiapine for the Reduction of Cocaine Use","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2008-02","conditions":"Cocaine Dependence, Cocaine Abuse, Cocaine Addiction","enrollment":60},{"nctId":"NCT00773162","phase":"PHASE3","title":"Flushing in Social Anxiety Disorder on Seroquel","status":"COMPLETED","sponsor":"START Clinic for Mood and Anxiety Disorders","startDate":"2008-10","conditions":"Social Anxiety Disorder","enrollment":21},{"nctId":"NCT01213836","phase":"PHASE4","title":"Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-11","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT00389064","phase":"PHASE3","title":"Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Anxiety Disorders","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo matching Seroquel XR","genericName":"Placebo matching Seroquel XR","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation designed to match the appearance and characteristics of Seroquel XR (quetiapine extended-release) for use as a control in clinical trials. Used for Clinical trial control for Seroquel XR studies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}